Skip to main content
IKT $1.32 +1.54%
IKT logo
IKT · Inhibikase Therapeutics, Inc.
Track IKT — free
$1.32 +0.02 (+1.54%) At close · Nov 20 Q2 2024 earnings call transcript
Market Cap
$185.16M
Shares
140.27M
Volume · Nov 20 1.11M Avg daily vol (3M) 580.26K
All webcasts

Earnings call · FY2026 Q3

Inhibikase Therapeutics, Inc. (IKT) Q3 2026 Earnings Call

Concluded Nov 10, 2026
Nov 10, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$0.10
Net income -$20.47M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 10, 2026
Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share.
10-Q report · filed Nov 10, 2026
Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document